Page 47 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

cancer: Targeting the epidermal growth factor receptor. Clin Mechanisms and therapeutic strategies. Cancer Treat Rev.
Cancer Res. 2001;7(10):2958-2970. 2018;65:1-10.
150. Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud doi: 10.1016/j.ctrv.2018.02.006
G. Cetuximab pharmacokinetics influences overall survival 160. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall
in patients with head and neck cancer. Ther Drug Monit. survival with osimertinib in untreated, EGFR-mutated
2016;38(5):567-572.
advanced NSCLC. N Engl J Med. 2020;382(1):41-50.
doi: 10.1097/ftd.0000000000000321
doi: 10.1056/NEJMoa1913662
151. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: 161. Wang Z, Yang JJ, Huang J, et al. Lung adenocarcinoma
Randomized phase II study of cetuximab in combination harboring EGFR T790M and in Trans C797S responds to
with carboplatin in stage IV triple-negative breast cancer. combination therapy of first- and third-generation EGFR
J Clin Oncol. 2012;30(21):2615-2623.
TKIs and shifts allelic configuration at resistance. J Thorac
doi: 10.1200/jco.2010.34.5579 Oncol. 2017;12(11):1723-1727.
152. Nabholtz JM, Abrial C, Mouret-Reynier MA, et al. doi: 10.1016/j.jtho.2017.06.017
Multicentric neoadjuvant phase II study of panitumumab 162. Okura N, Nishioka N, Yamada T, et al. ONO-7475, a novel
combined with an anthracycline/taxane-based AXL inhibitor, suppresses the adaptive resistance to initial
chemotherapy in operable triple-negative breast cancer: EGFR-TKI treatment in EGFR-mutated non-small cell lung
Identification of biologically defined signatures predicting cancer. Clin Cancer Res. 2020;26(9):2244-2256.
treatment impact. Ann Oncol. 2014;25(8):1570-1577.
doi: 10.1158/1078-0432.Ccr-19-2321
doi: 10.1093/annonc/mdu183
163. Choudhury NJ, Marra A, Sui JSY, et al. Molecular biomarkers
153. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, of disease outcomes and mechanisms of acquired resistance
Harari PM. Dual-agent molecular targeting of the to first-line osimertinib in advanced EGFR-mutant lung
epidermal growth factor receptor (EGFR): combining anti- cancers. J Thorac Oncol. 2023;18(4):463-475.
EGFR antibody with tyrosine kinase inhibitor. Cancer Res.
2004;64(15):5355-5362. doi: 10.1016/j.jtho.2022.11.022
doi: 10.1158/0008-5472.Can-04-0562 164. Meng Y, Bai R, Cui J. Precision targeted therapy for EGFR
mutation-positive NSCLC: Dilemmas and coping strategies.
154. Ferraro DA, Gaborit N, Maron R, et al. Inhibition of triple- Thorac Cancer. 2023;14(13):1121-1134.
negative breast cancer models by combinations of antibodies
to EGFR. Proc Natl Acad Sci U S A. 2013;110(5):1815-1820. doi: 10.1111/1759-7714.14858
doi: 10.1073/pnas.1220763110 165. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect
of anti-HER2/neu antibody depends on both innate and
155. Garrett JT, Arteaga CL. Resistance to HER2-directed adaptive immunity. Cancer Cell. 2010;18(2):160-170.
antibodies and tyrosine kinase inhibitors: mechanisms and
clinical implications. Cancer Biol Ther. 2011;11(9):793-800. doi: 10.1016/j.ccr.2010.06.014
doi: 10.4161/cbt.11.9.15045 166. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.
Mechanisms of disease: Understanding resistance to HER2-
156. Sankarapandian V, Rajendran RL, Miruka CO, et al. targeted therapy in human breast cancer. Nat Clin Pract
A review on tyrosine kinase inhibitors for targeted breast Oncol. 2006;3(5):269-280.
cancer therapy. Pathol Res Pract. 2024;263:155607.
doi: 10.1038/ncponc0509
doi: 10.1016/j.prp.2024.155607
167. Tseng PH, Wang YC, Weng SC, et al. Overcoming trastuzumab
157. Nagampalli RS, Vadla GP, Nadendla EK. Emerging strategies resistance in HER2-overexpressing breast cancer cells by
to overcome chemoresistance: Structural insights and using a novel celecoxib-derived phosphoinositide-dependent
therapeutic targeting of multidrug resistance-linked ATP- kinase-1 inhibitor. Mol Pharmacol. 2006;70(5):1534-1541.
binding cassette transporters. Int J Transl Med. 2025;5(1):6.
doi: 10.1124/mol.106.023911
doi: 10.3390/ijtm5010006
168. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J,
158. Pamphlett R, Bishop DP. Elemental biomapping of human Baselga J. Trastuzumab (herceptin), a humanized anti-Her2
tissues suggests toxic metals such as mercury play a role in receptor monoclonal antibody, inhibits basal and activated
the pathogenesis of cancer. Front Oncol. 2024;14:1420451.
Her2 ectodomain cleavage in breast cancer cells. Cancer Res.
doi: 10.3389/fonc.2024.1420451 2001;61(12):4744-4749.
159. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance 169. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2,
to EGFR targeted therapy in non-small cell lung cancer: a truncated form of the HER2 receptor, and response to

Volume 2 Issue 3 (2025) 41 doi: 10.36922/IMO025200022